Rebirth for R&D Start
29 November, 2002 by Pete YoungThe controversial seven-month freeze on Federal government R&D Start grants has thawed and AusIndustry is bracing itself for a pent-up flood of fresh applications.
Nextec sets up incubator for early-stage biotechs
27 November, 2002 by Melissa TrudingerMelbourne-based Nextec BioSciences has established an incubator facility for aspiring and early-stage biotech companies.
Ring the Bells
25 November, 2002 by Iain ScottIn its first year of publishing, Australian Biotechnology News has won four awards at the prestigious Australian Business Publishers Bell awards, held in Sydney last week.
QBF chief named
25 November, 2002 by Pete YoungThe Queensland government has chosen a bioscientist with extensive overseas big pharma and commercial experience to head its $100 million life science venture capital fund.
Retiring BresaGen CEO reflects on 15 years at the cutting edge
25 November, 2002 by Graeme O'NeillAs CEO of Adelaide's BresaGen, Dr John Smeaton is no doubt familiar with the ancient Chinese curse: "May you live in interesting times".
Kolling director wins Ramaciotti medal
22 November, 2002 by Susan WilliamsonProf Rob Baxter, Director of the Kolling Institute of Medical Research at the Royal North Shore Hospital and head of the Department of Molecular Medicine at the University of Sydney, has been awarded the 2002 Ramaciotti medal and $20,000 for his research on insulin-like growth factors and their binding proteins.
Qld biotech fund calls for proposals
14 November, 2002 by Pete YoungThe $100 million Queensland BioCapital Fund, whose formation was announced five months ago by the State government, is finally swinging its doors open for business.
We're publishing (and perishing) as fast as we can
13 November, 2002 by Graeme O'NeillFiddle with an old recipe and you may get an unpalatable, but not always unpredictable result.
INTERVIEW: Taking care of business
12 November, 2002 by Melissa TrudingerResearch institutes looking at ways to commercialise their intellectual property could do worse than examine the model used by Melbourne's Austin Research Institute.
NHMRC grants stick to the big smoke
12 November, 2002 by Pete YoungThe latest round of NHMRC funding grants shows Queensland's boast of being the most decentralised state does not extend to medical research.
Autogen, Antisense to raise $10m in separate placements
07 November, 2002 by Melissa TrudingerTwo Melbourne companies, Autogen and Antisense Therapeutics, have launched fully underwritten share placements to raise more than $10 million between them in capital.
IDG stable expands with new life science acquisition
06 November, 2002 by Staff WritersIDG Communications, publisher of Australian Biotechnology News, this week acquired two titles -- Today's Life Science and Lab News -- from Vertical Markets.
NHMRC fellowships to spur commercialisation
05 November, 2002 by Iain ScottThe National Health and Medical Research Council has awarded five new Industry Fellowships to encourage researchers to learn more about the commercial aspects of R&D.
Khan to raise Biota takover offer
31 October, 2002 by Pete YoungAn embarrassing oversight has forced a listed company controlled by self-styled "corporate rationaliser" Farooq Khan to lift its takeover offer for biotech Biota Holdings.
Microarrays and sequencers: Expressions in array technology
31 October, 2002 by Melissa TrudingerMicroarray technology is now a major tool available to the geneticist. The technology allows researchers to look at the expression of a vast array of genes simultaneously, and myriad applications have been found in the last few years. But deciding on the best microarray system for the needs of the research is a difficult task, with several choices available.
